Search Result

Results for "

antigen presentation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Aminopeptidase (3) Angiotensin Receptor (2) Antibiotic (2) Apoptosis (7) Autophagy (1) Bacterial (3) Beclin1 (1) Biochemical Assay Reagents (105) COX (1) DGK (1) DNA/RNA Synthesis (1) Epigenetic Reader Domain (1) FAK (1) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) Integrin (1) Interleukin Related (2) JAK (2) JNK (1) LILRB (1) Melanocortin Receptor (1) MHC (4) MMP (1) MyD88 (1) nAChR (1) Necroptosis (2) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) Orexin Receptor (OX Receptor) (1) PD-1/PD-L1 (3) Phosphatase (2) Prostaglandin Receptor (1) PROTACs (2) SHP2 (1) SLC39 (Zinc Transporter) (1) STAT (2) SWI/SNF Complex (1) Tim3 (2) TNF Receptor (1) Toll-like Receptor (TLR) (4) Transmembrane Glycoprotein (2) VEGFR (1) YAP (1) β-catenin (2)
By Research Areas:	Cancer (28) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (109) Metabolic Disease (1) Neurological Disease (2)
Oligonucleotides:	CpG ODNs (1) Adjuvant (2)

146

Inhibitors & Agonists

Fluorescent Dyes

111

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: HuR PSMA FLT3 CD74 Scavenger Receptor Class B type I (SR-BI）

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-161543

DHT/KLH	Biochemical Assay Reagents	Inflammation/Immunology
DHT/KLH is a conjugate of DHT (dihydrotestosterone) and keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-176778

BDM88951	Aminopeptidase	Inflammation/Immunology Cancer
BDM88951 (Compound 4 d) is a selective ERAP2 inhibitor with an IC₅₀ of 19  nM. BDM88951 significantly inhibits antigen presentation. BDM88951 can be used for autoimmune diseases and cancers research .

HY-161553

Biotin/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Biotin/KLH is an antigen-adjuvant conjugate that consists of Biotin and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161533

Digoxin/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Digoxin/BSA is an antigen-adjuvant conjugate of Digoxin (HY-B1049) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161560

Tacrolimus/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161541

Estradiol/BSA 1 Publications Verification	Biochemical Assay Reagents	Inflammation/Immunology
Estradiol/BSA is the antigen-adjuvant conjugate formed by the coupling of Estradiol (HY-B0141) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161552

T3/BSA	Biochemical Assay Reagents	Inflammation/Immunology
T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161526

T3/KLH	Biochemical Assay Reagents	Inflammation/Immunology
T3/KLH is an antigen-adjuvant conjugate formed by the coupling of T3 (thyroid hormone) with keyhole limpet hemocyanin (KLH). By coupling the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-117573

1Z105	Toll-like Receptor (TLR)	Inflammation/Immunology
1Z105 is an oral active TLR4/MD2 ligand. 1Z105 enhances dendritic cell maturation and antigen presentation and prevents rthritis .

HY-161566

DHT/BSA	Biochemical Assay Reagents	Inflammation/Immunology
DHT/BSA is an antigen-adjuvant conjugate formed by the coupling of DHT (dihydrotestosterone) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-158279

Gentamicin/OVA	Antibiotic Bacterial	Inflammation/Immunology
Gentamicin/OVA is an antigen-adjuvant conjugate conjugate of Gentamicin (HY-A0276A) and ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.

HY-157171

Ac-YR-NH2	MHC	Inflammation/Immunology
Ac-YR-NH2 is a small molecule modulator of MHC class II antigen presentation. Ac-YR-NH2 can influence peptide binding by MHC II to influence immune response .

HY-151464

SHP2/HDAC-IN-1	SHP2 Phosphatase HDAC	Inflammation/Immunology Cancer
SHP2/HDAC-IN-1 is a dual allosteric SHP2/HDAC inhibitor with IC₅₀ values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunoresearch .

HY-N15882

16:0 DNP Cap PE monoammonium	Biochemical Assay Reagents	Inflammation/Immunology
16:0 DNP Cap PE monoammonium is an antigenic lipid that plays a role in promoting antigen presentation on lipid bilayers .

HY-161583

Marijuana/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Marijuana/BSA is the antigen-adjuvant conjugate of Marijuana and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161549

Phosphotyrosine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161562

PROMETON/BSA	Biochemical Assay Reagents	Inflammation/Immunology
PROMETON/BSA is an antigen-adjuvant conjugate formed by the coupling of PROMETON with bovine serum albumin (BSA). By coupling the antigen to the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161529

Angiotensin I/BSA	Angiotensin Receptor	Inflammation/Immunology
Angiotensin I/BSA is an antigen-adjuvant conjugate of Angiotensin I and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-163556

COT/BSA	Biochemical Assay Reagents	Inflammation/Immunology
COT/BSA is the antigen-adjuvant conjugate of COT (cyclooctatetraene) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.

HY-NP0211

DHT-OVA	Biochemical Assay Reagents	Inflammation/Immunology
DHT-OVA is a conjugate of DHT (Dihydrotestosterone) and OVA peptide. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161542

Isoniazid/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Isoniazid/BSA is an antigen-adjuvant conjugate of Isoniazid (HY-B0329) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161540

Oxytetracycline/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Oxytetracycline/OVA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or destroy the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-163555

BZO/BSA	Biochemical Assay Reagents	Inflammation/Immunology
BZO/BSA is an antigen-adjuvant conjugate formed by the coupling of BZO (benzodiazepine) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161555

Clenbuterol/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Clenbuterol/KLH is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161554

Clenbuterol/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Clenbuterol/BSA is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161532

Eugenol/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Eugenol/OVA is an antigen-adjuvant conjugate formed by the conjugation of Eugenol (HY-N0337) with Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161591

SEM/BSA	Biochemical Assay Reagents	Inflammation/Immunology
SEM/BSA is an antigen-adjuvant conjugate formed by the conjugation of SEM (furanesalin) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161594

Furazolidone/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Furazolidone/BSA is the antigen-adjuvant conjugate of Furazolidone (HY-B1336) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161530

Angiotensin II/BSA	Angiotensin Receptor	Inflammation/Immunology
Angiotensin II/BSA is an antigen-adjuvant conjugate formed by the coupling of Angiotensin II with bovine serum albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161558

Ractopamine/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Ractopamine/KLH is an antigen-adjuvant conjugate of Ractopamine (HY-113781) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-163553

Metronidazole/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Metronidazole/BSA is an antigen-adjuvant conjugate of Metronidazole (HY-B0318) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161544

Cholyglycine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Cholyglycine/BSA is a conjugate of Cholyglycine and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-NP0250

Kanamycin-BSA	Biochemical Assay Reagents	Inflammation/Immunology
Kanamycin-BSA is a conjugate of Kanamycin (HY-16566) and BSA. By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .

HY-161580

3-Nitrotyrosine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
3-Nitrotyrosine/BSA is an antigen-adjuvant conjugate formed by the conjugation of 3-Nitrotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.

HY-161590

AHD/BSA	Biochemical Assay Reagents	Inflammation/Immunology
AHD/BSA is the antigen-adjuvant conjugate of AHD (furan-2-carboxylic acid) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161586

Chloramphenicol/BSA	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP Biochemical Assay Reagents	Inflammation/Immunology
Chloramphenicol/BSA is the antigen-adjuvant conjugate formed by the coupling of Chloramphenicol (HY-B0239) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161546

Melamine/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Melamine/KLH is an antigen-adjuvant conjugate formed by coupling Melamine (HY-Y1117) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161535

Oxytetracycline/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Oxytetracycline/BSA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161528

T3/OVA	Biochemical Assay Reagents	Inflammation/Immunology
T3/OVA is an antigen-adjuvant conjugate formed by conjugating T3 (thyroxine) with ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161557

Ractopamine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Ractopamine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Ractopamine (HY-113781) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161589

GABA/KLH	Biochemical Assay Reagents	Inflammation/Immunology
GABA/KLH is an antigen-adjuvant conjugate formed by the coupling of GABA (γ-aminobutyric acid) with keyhole limpet hemocyanin (KLH). By coupling the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161534

Sulfadiazine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Sulfadiazine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Sulfadiazine (HY-B0273) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161588

GABA/BSA	Biochemical Assay Reagents	Inflammation/Immunology
GABA/BSA is an antigen-adjuvant conjugate formed by the coupling of GABA (γ-aminobutyric acid) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161559

Sudan I/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Sudan I/OVA is an antigen-adjuvant conjugate formed by coupling Sudan I (HY-D0024) with Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161585

Diethylstilbestrol/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Diethylstilbestrol/KLH is an antigen-adjuvant conjugate formed by the coupling of Diethylstilbestrol (HY-14598) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161587

Chloramphenicol/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Chloramphenicol/OVA is a conjugate of Chloramphenicol (HY-B0239) and Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the production of antigen-specific T cells.

HY-161581

Metronidazole/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Metronidazole/OVA is a conjugate of Metronidazole (HY-B0318) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-NP0255

Amoxicillin-BSA	Biochemical Assay Reagents	Inflammation/Immunology
Amoxicillin-BSA is a conjugate of Amoxicillin (HY-B0467A) and BSA. By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .

HY-NP0248

Ciprofloxacin-BSA	Biochemical Assay Reagents	Inflammation/Immunology
Ciprofloxacin-BSA is a conjugate of Ciprofloxacin (HY-B0356) and BSA. By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .

HY-161545

Sudan I/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Sudan I/BSA is the antigen-adjuvant conjugate formed by Sudan I (HY-D0024) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

Cat. No.	Product Name	Target	Research Area

HY-P5623

RVG 1 Publications Verification RVG29; RDP; Rabies Virus Glycoprotein-29	nAChR Interleukin Related	Neurological Disease Inflammation/Immunology
RVG (RVG29) is a blood-brain barrier-permeable peptide derived from rabies virus glycoprotein, which binds to the α-7 subunit of neuronal nicotinic acetylcholine receptor (AchR). RVG efficiently delivers drugs to nerve cells and antigen-presenting cells in a targeted manner, and enhances the efficiency of antigen presentation and drug delivery .

HY-P2114

IT9302	Peptides	Cancer
IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells .

HY-P5488

BDC2.5 Mimotope 1040-63	Peptides	Others
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

HY-P2674

KDEL	MHC	Inflammation/Immunology Cancer
KDEL is a tetrapeptide serving as an endoplasmic reticulum (ER) retrieval/retention signal. KDEL can target and deliver exogenous antigen peptides to the ER, significantly enhance and prolong MHC class I molecule presentation, and effectively boost anti-tumor immune responses .

HY-P11280A

PRAME peptide (425-433) acetate	Melanocortin Receptor	Cancer
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen *PRAME (Preferentially Expressed Antigen* in Melanoma)*. PRAME peptide (425-433) acetate is restricted by HLA-A02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99236

Bexmarilimab 1 Publications Verification FP-1305	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC₅₀ value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma .

HY-P990115

Anti-Mouse OX40/CD134 Antibody (OX-86)	Orexin Receptor (OX Receptor)	Inflammation/Immunology Cancer
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonal antibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 ⁺ T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .

HY-P990185

Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S)	MHC	Inflammation/Immunology Cancer
Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/rat MHC Class II. Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S) reacts with mouse MHC Class II alloantigen I-Ek and the rat MHC class II alloantigen RT1D. Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S) blocks antigen presentation. Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S) can be used for the research of immunology and cancer .

HY-P990119

Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58)	Inhibitory Antibodies	Inflammation/Immunology
Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) is an anti-mouse Kappa Immunoglobulin Light Chain IgG1 monoclonal antibody. Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) can reduce the phosphorylation levels of Src and Syk in B cells and the antigen presentation ability of B cells. Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) can be used for research on immunology .

HY-P990716

Sabestomig AZD7789	PD-1/PD-L1 Tim3	Inflammation/Immunology
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .

HY-P992314

ASD141	Integrin PD-1/PD-L1	Cancer
ASD141 is a mouse IgG1 antibody targeting mouse CD11b and a CD11b antagonist. ASD141 remodels the tumor microenvironment, enhances antigen presentation ability, and induces PD-L1 expression. ASD141 can be used for the research of colon cancer .

HY-P991804

Anti-Mouse CD79b Antibody (HM79b)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD79b Antibody (HM79b) reacts with the mouse CD79b. CD79b participates in the signal transduction cascade activated by the B cell antigen receptor complex (BCR), ultimately leading to complex internalization, transport to late endosomes, and antigen presentation. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978) .

HY-P992062

Anti-Mouse CD80 Antibody (TKMG48)	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect PD-1 agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8 ⁺ T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1 .

HY-P992389

IO-202	LILRB	Cancer
IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors .

HY-P992454

S095018	Tim3	Cancer
S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 ⁺T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .

HY-P992159

Anti-ZnT8 Antibody (mAb43)	SLC39 (Zinc Transporter)	Metabolic Disease Inflammation/Immunology
Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes .

Cat. No.	Product Name		Classification

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909		CpG ODNs
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC₅₀ of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-156087

Cholicamideβ		Adjuvant
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .

HY-159749

M902		Adjuvant
M902 is a new type of mineral oil-based adjuvant, which belongs to oil-in-water (O/W) emulsion. It rapidly stimulates the body to produce an immune response, has a low oil content, high safety, can induce natural immune responses, improve the efficiency of antigen uptake and presentation, induce the production of various cytokines, and increase the level of specific antibodies against antigens in the animal body. It is applicable to various veterinary vaccines, including inactivated vaccines and genetically engineered subunit vaccines, such as vaccine for Porcine Circovirus and Mycoplasma Hyopneumoniae.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

antigen presentation

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products